412 related articles for article (PubMed ID: 29429807)
1. Post hoc analysis of the efficacy of the 13-valent pneumococcal conjugate vaccine against vaccine-type community-acquired pneumonia in at-risk older adults.
Suaya JA; Jiang Q; Scott DA; Gruber WC; Webber C; Schmoele-Thoma B; Hall-Murray CK; Jodar L; Isturiz RE
Vaccine; 2018 Mar; 36(11):1477-1483. PubMed ID: 29429807
[TBL] [Abstract][Full Text] [Related]
2. Exploratory efficacy endpoints in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA).
Webber C; Patton M; Patterson S; Schmoele-Thoma B; Huijts SM; Bonten MJ;
Vaccine; 2017 Mar; 35(9):1266-1272. PubMed ID: 28173960
[TBL] [Abstract][Full Text] [Related]
3. A post-hoc analysis of serotype-specific vaccine efficacy of 13-valent pneumococcal conjugate vaccine against clinical community acquired pneumonia from a randomized clinical trial in the Netherlands.
Gessner BD; Jiang Q; Van Werkhoven CH; Sings HL; Webber C; Scott D; Gruber WC; Grobbee DE; Bonten MJM; Jodar L
Vaccine; 2019 Jul; 37(30):4147-4154. PubMed ID: 31155413
[TBL] [Abstract][Full Text] [Related]
4. Post-hoc analysis of a randomized controlled trial: Diabetes mellitus modifies the efficacy of the 13-valent pneumococcal conjugate vaccine in elderly.
Huijts SM; van Werkhoven CH; Bolkenbaas M; Grobbee DE; Bonten MJM
Vaccine; 2017 Aug; 35(34):4444-4449. PubMed ID: 28410813
[TBL] [Abstract][Full Text] [Related]
5. A public health evaluation of 13-valent pneumococcal conjugate vaccine impact on adult disease outcomes from a randomized clinical trial in the Netherlands.
Gessner BD; Jiang Q; Van Werkhoven CH; Sings HL; Webber C; Scott D; Neuzil KM; O'Brien KL; Wunderink RG; Grobbee DE; Bonten MJM; Jodar L
Vaccine; 2019 Sep; 37(38):5777-5787. PubMed ID: 29861177
[TBL] [Abstract][Full Text] [Related]
6. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults.
Bonten MJ; Huijts SM; Bolkenbaas M; Webber C; Patterson S; Gault S; van Werkhoven CH; van Deursen AM; Sanders EA; Verheij TJ; Patton M; McDonough A; Moradoghli-Haftvani A; Smith H; Mellelieu T; Pride MW; Crowther G; Schmoele-Thoma B; Scott DA; Jansen KU; Lobatto R; Oosterman B; Visser N; Caspers E; Smorenburg A; Emini EA; Gruber WC; Grobbee DE
N Engl J Med; 2015 Mar; 372(12):1114-25. PubMed ID: 25785969
[TBL] [Abstract][Full Text] [Related]
7. Distribution of 13-valent pneumococcal conjugate vaccine Streptococcus pneumoniae serotypes in US adults aged ≥50 years with community-acquired pneumonia.
Sherwin RL; Gray S; Alexander R; McGovern PC; Graepel J; Pride MW; Purdy J; Paradiso P; File TM
J Infect Dis; 2013 Dec; 208(11):1813-20. PubMed ID: 24092845
[TBL] [Abstract][Full Text] [Related]
8. Prevention of adult pneumococcal pneumonia with the 13-valent pneumococcal conjugate vaccine: CAPiTA, the community-acquired pneumonia immunization trial in adults.
Isturiz R; Webber C
Hum Vaccin Immunother; 2015; 11(7):1825-7. PubMed ID: 26076136
[TBL] [Abstract][Full Text] [Related]
9. Pneumococcal conjugate vaccine use for the prevention of pneumococcal disease in adults <50 years of age.
Isturiz RE; Hall-Murray C; McLaughlin JM; Snow V; Schmoele-Thoma B; Webber C; Thompson A; Scott DA
Expert Rev Vaccines; 2018 Jan; 17(1):45-55. PubMed ID: 29183235
[TBL] [Abstract][Full Text] [Related]
10. 13-Valent vaccine serotype pneumococcal community acquired pneumonia in adults in high clinical risk groups.
Daniel P; Rodrigo C; Bewick T; Sheppard C; Greenwood S; McKeever TM; Trotter C; Lim WS
Vaccine; 2018 Mar; 36(12):1614-1620. PubMed ID: 29439865
[TBL] [Abstract][Full Text] [Related]
11. Streptococcus pneumoniae serotype 3 is masking PCV13-mediated herd immunity in Canadian adults hospitalized with community acquired pneumonia: A study from the Serious Outcomes Surveillance (SOS) Network of the Canadian immunization research Network (CIRN).
LeBlanc JJ; ElSherif M; Ye L; MacKinnon-Cameron D; Ambrose A; Hatchette TF; Lang ALS; Gillis HD; Martin I; Demczuk W; Andrew MK; Boivin G; Bowie W; Green K; Johnstone J; Loeb M; McCarthy AE; McGeer A; Semret M; Trottier S; Valiquette L; Webster D; McNeil SA
Vaccine; 2019 Aug; 37(36):5466-5473. PubMed ID: 31345638
[TBL] [Abstract][Full Text] [Related]
12. Effects of 13-valent pneumococcal conjugate vaccination of adults on lower respiratory tract infections and antibiotic use in primary care: secondary analysis of a double-blind randomized placebo-controlled study.
van Werkhoven CH; Bolkenbaas M; Huijts SM; Verheij TJM; Bonten MJM
Clin Microbiol Infect; 2021 Jul; 27(7):995-999. PubMed ID: 32971253
[TBL] [Abstract][Full Text] [Related]
13. Pneumococcal conjugate vaccine against serotype 3 pneumococcal pneumonia in adults: A systematic review and pooled analysis.
McLaughlin JM; Jiang Q; Gessner BD; Swerdlow DL; Sings HL; Isturiz RE; Jodar L
Vaccine; 2019 Oct; 37(43):6310-6316. PubMed ID: 31522807
[TBL] [Abstract][Full Text] [Related]
14. Pneumococcal serotypes in adults hospitalized with community-acquired pneumonia in Greece using urinary antigen detection tests: the EGNATIA study, November 2017 - April 2019.
Liapikou A; Konstantinidis A; Kossyvaki V; Skiadas J; Menegas D; Méndez C; Beavon R; Begier E; Gessner BD; Milionis H; Tsimihodimos V; Baxevanos G; Argiriadou T; Terrovitou C; Toumbis M;
Hum Vaccin Immunother; 2022 Nov; 18(5):2079923. PubMed ID: 35703733
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Hospitalization for Community-Acquired Pneumonia in Older US Adults: A Test-Negative Design.
McLaughlin JM; Jiang Q; Isturiz RE; Sings HL; Swerdlow DL; Gessner BD; Carrico RM; Peyrani P; Wiemken TL; Mattingly WA; Ramirez JA; Jodar L
Clin Infect Dis; 2018 Oct; 67(10):1498-1506. PubMed ID: 29790925
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of the 13-valent pneumococcal conjugate vaccine against adult pneumonia in Italy: a case-control study in a 2-year prospective cohort.
Prato R; Fortunato F; Cappelli MG; Chironna M; Martinelli D
BMJ Open; 2018 Mar; 8(3):e019034. PubMed ID: 29581200
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23) against Pneumococcal Disease in the Elderly: Systematic Review and Meta-Analysis.
Falkenhorst G; Remschmidt C; Harder T; Hummers-Pradier E; Wichmann O; Bogdan C
PLoS One; 2017; 12(1):e0169368. PubMed ID: 28061505
[TBL] [Abstract][Full Text] [Related]
18. 13-Valent Pneumococcal Conjugate Vaccine: A Review of Its Use in Adults.
Plosker GL
Drugs; 2015 Sep; 75(13):1535-46. PubMed ID: 26242768
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against vaccine serotype pneumococcal pneumonia in adults: A case-control test-negative design study.
Lawrence H; Pick H; Baskaran V; Daniel P; Rodrigo C; Ashton D; Edwards-Pritchard RC; Sheppard C; Eletu SD; Litt D; Fry NK; Rose S; Trotter C; McKeever TM; Lim WS
PLoS Med; 2020 Oct; 17(10):e1003326. PubMed ID: 33095759
[TBL] [Abstract][Full Text] [Related]
20. The impact of 13-valent pneumococcal conjugate vaccination on virus-associated community-acquired pneumonia in elderly: Exploratory analysis of the CAPiTA trial.
Huijts SM; Coenjaerts FEJ; Bolkenbaas M; van Werkhoven CH; Grobbee DE; Bonten MJM;
Clin Microbiol Infect; 2018 Jul; 24(7):764-770. PubMed ID: 29050992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
